CRISPR-Cas9 democratized genome editing because it's programmable. Earlier targeted-editing systems (zinc-finger nucleases, TALENs) required a custom protein for each target site; CRISPR just needs a 20-nucleotide guide RNA.
Doudna and Charpentier won the 2020 Nobel for the 2012 paper showing this works in cell-free systems. Within a decade, CRISPR became standard in molecular biology labs, was approved for sickle cell disease (Casgevy, 2023), and progressed to clinical trials for dozens of conditions. Base editors and prime editors extend the precision; the off-target and delivery problems remain the engineering frontier.
